Professor Sir Michael Rawlins reappointed as NICE chairman
pharmafile | November 24, 2011 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | NICE, Rawlins
The National Institute for Health and Clinical Excellence (NICE) has reappointed Professor Sir Michael Rawlins as NICE chairman for a further one-year term.
His reappointment will allow Professor Rawlins to oversee the final year of NICE as a special health authority, and will commence from 1 April 2012 to 31 March 2013.
From 2013 NICE – under a new chairman – will be established as a non-departmental public body, and will have additional responsibilities for social care, subject to the passage of the Health and Social Care Bill.
Professor Rawlins will also be the president-elect of the Royal Society for Medicine from July 2012.
As well as his positions at NICE and the Royal Society, he is also an honorary professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne.
Before these positions, he was the Ruth and Lionel Jacobson professor of clinical pharmacology at the University of Newcastle upon Tyne from 1973 to 2006.
Professor Rawlins said: “Chairing NICE has been the high point of my professional career. But, the Institute’s national and international reputation is due to the efforts of its board, its dedicated staff, and to the army of stakeholders and members of its advisory bodies who play such a crucial role.
“The opportunity to work with them for another 12 months was too good to resist.”
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
